Heart Failure

 
Study: Two-thirds of COVID-19 Hospitalizations Attributable to 4 Major Cardiometabolic Conditions
February 26, 2021

A new modeling study estimates that 64% of US COVID-19 hospitalizations were attributable to at least 1 of 4 pre-existing cardiometabolic conditions.

FDA Grants Label Expansion for Heart Failure Treatment
February 18, 2021

FDA approved the fixed-dose combination heart failure drug sacubitril/valsartan to reduce risk of CV death and hospitalization in patients with chronic heart failure.

George Bakris, MD: Heart Failure, Renal Disease, CV Risk Research is on Fire
February 03, 2021

Video: George Bakris, MD says over the next 3 years there is going to be an "explosion" in the number of studies we see in heart failure, diabetic kidney disease, and CV risk in general.